Jeroen Bakker joined Novo Seeds in 2018 as a Senior Associate.
Prior to joining Novo, Jeroen worked as an Associate at M Ventures, the corporate venture capital arm of Merck, where he focused on early-stage healthcare investments in Europe, United States and company creation for the Israel Incubator. He co-led the investment in Artsavit and served on the Boards of Vaximm and Artsavit as an observer. Before M Ventures, Jeroen was active as a consultant where he was instrumental in acquiring over EUR 10 million in non-dilutive funding for biotech and translational academic research. Jeroen started his career in biotech at Syntaxin (acquired by Ipsen) working on target identification.
Jeroen holds a PhD in Immunology from the University of Amsterdam and an MSc degree in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and is currently part of REBBLS, a networking organization focusing on young biotech entrepreneurs in Denmark.